Did Sangamo Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SGMO
Portfolio Pulse from
Levi & Korsinsky is investigating Sangamo Therapeutics for potential federal securities law violations after Pfizer returned development rights for a hemophilia A gene therapy candidate.
January 14, 2025 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics is under investigation by Levi & Korsinsky for potential securities law violations after Pfizer returned rights for a hemophilia A therapy.
The investigation by Levi & Korsinsky could lead to legal challenges for Sangamo Therapeutics, potentially affecting investor confidence. The return of rights by Pfizer suggests possible issues with the therapy's viability, impacting Sangamo's future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100